|
BioPartners Announces CHMP Positive Opinion for its Biosimilar Recombinant Human Growth Hormone - Valtropin™ |
|
|
|
24 Feb 2006 |
Announced a positive opinion from the European Medicines Agency's Committee on Medicinal Products for Human Use (CHMP)
ZUG, Switzerland | Feb 24, 2006 | BioPartners, a global, privately owned biopharmaceuticals company has received a positive opinion from the European Medicines Agency's Committee on Medicinal Products for Human Use (CHMP) for its similar biological medicinal product Valtropin™, containing recombinant human growth hormone.
Commenting on this, Professor Paul Saenger, Professor of Paediatrics at the Albert Einstein College of Medicine in New York, USA and Immediate Past President, Lawson Wilkins Paediatric Endocrine Society said “if it is granted marketing authorisation, Valtropin™ will provide paediatric endocrinologists with a more cost-effective treatment option for growth disorders compared to the currently marketed growth hormone preparations and this in turn allow us to treat more patients, which is great news”.
“A positive opinion from the CHMP is a key milestone in our efforts and it demonstrates BioPartners' commitment and dedication to the development of competitive biosimilar products” stated Mr Jean-Noël Treilles, CEO of BioPartners. “We anticipate an approval for Valtropin™ and this will strengthen our development programme for our innovative delayed release rhGH formulation currently in Phase III. We are looking forward to providing healthcare professionals and patients with this innovative treatment in the very near future”.
About Biopartners
Headquartered in Baar, Switzerland with an affiliate in Germany, BioPartners (www.biopartners.com) is a global biopharmaceuticals company and a leader in the emerging field of multi-source biopharmaceuticals. BioPartners' mission is to develop patentable and innovative formulations of “first generation” biopharmaceuticals as well as advanced delivery systems that may improve patient compliance to its product portfolio. BioPartners is developing a comprehensive range of biopharmaceutical products that may offer life-saving therapeutic benefits across many therapeutic areas, including oncology, virology, haematology, endocrinology and neurology.
BioPartners has submitted a second dossier to the EMEA and has two products in the pipeline currently in clinical Phase III.
For further information on BioPartners, please contact:
Pascal Broennimann, Head of Finance and Administration
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Marie-Joëlle Gaufrès, Head of Commercial Operations
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Phone: +41 (0)41 766 20 80
www.biopartners.com
Notes to Editors:
BioPartners is a DLJ Merchant Banking Partners investment. DLJ Merchant Banking is a part of Credit-Suisse private equity.
BioPartners has partnered LG Life Sciences, the leading South Korean manufacturer of biopharmaceuticals and other cutting edge companies for the development and manufacture of its portfolio of drugs.
SOURCE: BioPartners |
